Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone in Oral Leukoplakia
NCT00099021Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2003
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pioglitazone in head and neck cancer (HNC), sponsored by National Cancer Institute. Primary endpoint: Patients' Overall Response at 16 weeks. Started Jun 2003; status: completed.
02
Drugs
pioglitazone
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT00099021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00099021.